865 related articles for article (PubMed ID: 26082629)
21. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.
Brusselle G; Price D; Gruffydd-Jones K; Miravitlles M; Keininger DL; Stewart R; Baldwin M; Jones RC
Int J Chron Obstruct Pulmon Dis; 2015; 10():2207-17. PubMed ID: 26527869
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods.
Kwak MS; Kim E; Jang EJ; Kim HJ; Lee CH
Int J Chron Obstruct Pulmon Dis; 2015; 10():2365-76. PubMed ID: 26604734
[TBL] [Abstract][Full Text] [Related]
23. Categorization of COPD patients in Turkey via GOLD 2013 strategy document: ALPHABET study.
Gunen H; Yilmaz M; Aktas O; Ergun P; Ortakoylu MG; Demir A; Cetinkaya P; Gurgun A; Otlu M; Cilli A; Yilmaz U; Kokturk N; Candemir I; Yakar HI; Ar I; Konya A
Int J Chron Obstruct Pulmon Dis; 2015; 10():2485-94. PubMed ID: 26622176
[TBL] [Abstract][Full Text] [Related]
24. Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016.
Bloom CI; Elkin SL; Quint JK
Int J Chron Obstruct Pulmon Dis; 2019; 14():279-287. PubMed ID: 30774325
[TBL] [Abstract][Full Text] [Related]
25. Dual bronchodilation vs triple therapy in the "real-life" COPD DACCORD study.
Buhl R; Criée CP; Kardos P; Vogelmeier CF; Kostikas K; Lossi NS; Worth H
Int J Chron Obstruct Pulmon Dis; 2018; 13():2557-2568. PubMed ID: 30197512
[TBL] [Abstract][Full Text] [Related]
26. An evaluation of early medication use for COPD: a population-based cohort study.
Falk J; Dik N; Bugden S
Int J Chron Obstruct Pulmon Dis; 2016; 11():3101-3108. PubMed ID: 27994449
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study.
Di Marco F; Santus P; Terraneo S; Peruzzi E; Muscianisi E; Ripellino C; Pegoraro V
NPJ Prim Care Respir Med; 2017 Sep; 27(1):51. PubMed ID: 28883469
[TBL] [Abstract][Full Text] [Related]
28. Adherence to GOLD guideline treatment recommendations among pulmonologists in Turkey.
Sen E; Guclu SZ; Kibar I; Ocal U; Yilmaz V; Celik O; Cimen F; Topcu F; Orhun M; Tereci H; Konya A; Ar I; Saryal S
Int J Chron Obstruct Pulmon Dis; 2015; 10():2657-63. PubMed ID: 26715844
[TBL] [Abstract][Full Text] [Related]
29. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
[TBL] [Abstract][Full Text] [Related]
30. Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort.
Singh MP
Int J Chron Obstruct Pulmon Dis; 2013; 8():613-9. PubMed ID: 24353411
[TBL] [Abstract][Full Text] [Related]
31. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.
Price D; Miravitlles M; Pavord I; Thomas M; Wedzicha J; Haughney J; Bichel K; West D
NPJ Prim Care Respir Med; 2016 Nov; 26():16061. PubMed ID: 27808096
[TBL] [Abstract][Full Text] [Related]
32. Inhaled treatment of COPD: a Delphi consensus statement.
Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
[TBL] [Abstract][Full Text] [Related]
33. Symptomatic burden of COPD for patients receiving dual or triple therapy.
Chen S; Small M; Lindner L; Xu X
Int J Chron Obstruct Pulmon Dis; 2018; 13():1365-1376. PubMed ID: 29731624
[TBL] [Abstract][Full Text] [Related]
34. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
36. When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals.
Gaduzo S; McGovern V; Roberts J; Scullion JE; Singh D
Int J Chron Obstruct Pulmon Dis; 2019; 14():391-401. PubMed ID: 30863039
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.
Qaseem A; Wilt TJ; Weinberger SE; Hanania NA; Criner G; van der Molen T; Marciniuk DD; Denberg T; Schünemann H; Wedzicha W; MacDonald R; Shekelle P; ; ; ;
Ann Intern Med; 2011 Aug; 155(3):179-91. PubMed ID: 21810710
[TBL] [Abstract][Full Text] [Related]
38. Can Assessment of Disease Burden Prior to Changes in Initial COPD Maintenance Treatment Provide Insight into Remaining Unmet Needs? A Retrospective Database Study in UK Primary Care.
Landis SH; Wurst K; Le HV; Bonar K; Punekar YS
COPD; 2017 Feb; 14(1):80-85. PubMed ID: 27819513
[TBL] [Abstract][Full Text] [Related]
39. Patterns of use of long-acting bronchodilators in patients with COPD: A nationwide follow-up study of new users in New Zealand.
Parkin L; Barson D; Zeng J; Horsburgh S; Sharples K; Dummer J
Respirology; 2018 Jun; 23(6):583-592. PubMed ID: 29265705
[TBL] [Abstract][Full Text] [Related]
40. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?
Salama RO; Young PM; Rogueda P; Lallement A; Iliev I; Traini D
Expert Opin Pharmacother; 2011 Aug; 12(12):1913-32. PubMed ID: 21714776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
